Maple Grove, Minnesota — October 7, 2025 — Leads & Copy — Peli BioThermal has acquired Evo from BioLife Solutions, expanding its portfolio of temperature-controlled logistics solutions. The acquisition includes cryogenic shippers and the evoIS® technology platform, aimed at the cell and gene therapy sector.
The acquisition enhances Peli BioThermal’s ability to offer cold chain solutions and engage with pharmaceutical, biopharmaceutical, and clinical supply customers. Evo users will benefit from direct sourcing through Peli BioThermal, while the Evo product line will see accelerated development and innovation.
The addition of Evo products is significant for the Cell and Gene Therapy market, where cryogenic transport, precision, reliability, and flexibility are crucial. According to Sam Herbert, CEO of Peli BioThermal, the acquisition reinforces their commitment to solving customer cold chain challenges.
The Evo portfolio will integrate with Peli BioThermal’s existing solutions, including Crēdo™ reusable shippers, NanoCool™ systems, Crēdo Vault™ bulk shipper, and Vēro One™ single-use dry ice shipper. This provides customers with flexibility in choosing solutions for sustainability, performance, or operational simplicity.
According to Platinum Equity Co-President Jacob Kotzubei and Managing Director Matthew Louie, the acquisition enables Peli BioThermal to offer a full spectrum of temperature-controlled solutions and access new high-growth markets. The Bruce Township, MI operations and team associated with Evo will remain part of Peli BioThermal.
To learn more about Peli BioThermal’s expanded portfolio and its support for Cell and Gene Therapy logistics, visit the company’s website.
Source: Peli BioThermal
